Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference48 articles.
1. Cancer statistics, 2021;Siegel;CA Cancer J Clin,2021
2. Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review;Ong;Transl Androl Urol,2021
3. Evolution of androgen receptor targeted therapy for advanced prostate cancer;Wong;Nat Rev Clin Oncol,2014
4. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically;Ryan;J Clin Oncol,2011
5. Mechanisms of resistance in castration-resistant prostate cancer (CRPC);Chandrasekar;Transl Androl Urol,2015
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews;Frontiers in Oncology;2023-09-27
2. Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells;PLOS ONE;2022-12-22
3. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study;The Lancet Oncology;2022-11
4. Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1H-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor;Journal of Medicinal Chemistry;2022-09-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3